4.7 Article

The European Union CREATE Project: A model for international standardization of allergy diagnostics and vaccines

期刊

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 122, 期 5, 页码 882-889

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2008.07.030

关键词

Allergen standardisation; allergic diseases; allergy diagnostics; allergy vaccines; asthma; IgE; immunotherapy; purified allergens; genetic engineering

资金

  1. European Union [G6RD-CT-2001-00582]
  2. ALK-Abello
  3. Aliergopharma Joachim Ganzer KG
  4. ASAC Pharmaceutical International SA
  5. Biomay AG
  6. Laboratorios Leti
  7. HAL Allergy BV
  8. Indoor Biotechnologies Ltd
  9. Stallergenes SA
  10. Ministerio de Ciencia y Tecnologia
  11. GlaxoSmithKline
  12. German Research Society
  13. Research Fund of the German Food Industry
  14. Monsanto Company
  15. European Directorate for the Quality of Medicines and Health Care

向作者/读者索取更多资源

Allergen measurements are used extensively in the formulation of allergy diagnostics and vaccines, yet no purified international allergen standards are available for calibration purposes. The aims of the European Union CREATE project were to develop international standards with verifiable allergen content. Purified natural and recombinant allergens were analyzed by means of SDS-PAGE, mass spectrometry, circular dichroism spectra, and small-angle x-ray scattering. IgE reactivity was assessed by means of direct RAST, RAST inhibition, immunoblotting, and basophil histamine release with sera from 961 allergic patients. Three recombinant allergens, rBet v 1, rPh1 p 5a, and rDer p 2, were structurally indistinguishable from their natural counterparts and showed excellent IgE reactivity suitable for use as certified reference materials. A second tier of allergens (rPhl p 5b, rOle e1, rDer p 1, rDer f 1, and rDer f 2) was identified that could provide suitable candidates for certified reference materials with minor improvements to the recombinant proteins. Only rPhl p I was considered unsuitable as a reference material. Quantitative ELISAs were identified that accurately measured each allergen, except for rPhl p 1. The CREATE project has provided a major step forward in allergen standardization and provides a model for the development of a comprehensive panel of international reference preparations that will harmonize allergen measurements worldwide. (J Allergy Clin Immunol 2008;122:882-9.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据